These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20194156)

  • 1. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.
    Madan S; Kyle RA; Greipp PR
    Mayo Clin Proc; 2010 Mar; 85(3):300. PubMed ID: 20194156
    [No Abstract]   [Full Text] [Related]  

  • 2. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
    Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
    Kyle RA; Remstein ED; Therneau TM; Dispenzieri A; Kurtin PJ; Hodnefield JM; Larson DR; Plevak MF; Jelinek DF; Fonseca R; Melton LJ; Rajkumar SV
    N Engl J Med; 2007 Jun; 356(25):2582-90. PubMed ID: 17582068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
    Greipp PR; Kyle RA
    Blood; 1983 Jul; 62(1):166-71. PubMed ID: 6407546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic analysis of high-risk smoldering multiple myeloma.
    López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
    Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["Benign" monoclonal gammopathy: prognostic value of initial bone marrow study].
    Grau E; Ayats R; Puig J; Domingo A; Pujol-Moix N
    Sangre (Barc); 1985; 30(3):308-19. PubMed ID: 4035526
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using aspirates for multiple myeloma research probably excludes important data.
    Ely S
    Br J Haematol; 2006 Jul; 134(2):245-6. PubMed ID: 16846488
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual morphologic presentation of plasma cells during the course of a multiple myeloma.
    Salignac S; Buisine J; Lesesve JF
    Haematologica; 2004 Apr; 89(4):EIM04. PubMed ID: 15075107
    [No Abstract]   [Full Text] [Related]  

  • 11. Auer rod-like inclusions in plasma cells in multiple myeloma.
    Ho WK; Zantomio D
    J Clin Pathol; 2014 Jun; 67(6):547-8. PubMed ID: 24625389
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
    Pasqualetti P; Colantonio D; Casale R
    Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mimics of megakaryocytes: giant bizarre myeloma cells.
    Liu H; Li S
    Blood; 2016 Aug; 128(6):882. PubMed ID: 28092900
    [No Abstract]   [Full Text] [Related]  

  • 15. Bone marrow plasma cell infiltration in multiple myeloma.
    de Gramont A; Benitez O; Smadja N; Brissaud P; Sirinelli A; Hubert D; Krulik M; Debray J
    Br J Haematol; 1984 Jun; 57(2):351-3. PubMed ID: 6733051
    [No Abstract]   [Full Text] [Related]  

  • 16. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.
    Steensma DP; Gertz MA; Greipp PR; Kyle RA; Lacy MQ; Lust JA; Offord JR; Plevak MF; Therneau TM; Witzig TE
    Blood; 2001 Apr; 97(8):2522-3. PubMed ID: 11290618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of smoldering multiple myeloma.
    Rajkumar SV; Larson D; Kyle RA
    N Engl J Med; 2011 Aug; 365(5):474-5. PubMed ID: 21812699
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
    Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.